CrestOptics selected by Akoya Biosciences for spatial biology collaboration
Rome, IT, 29 June 2021: CrestOptics SpA, a manufacturer of high-end microscopy solutions and advanced systems for fluorescence microscopy and diagnostic applications, today announced that it has been selected by Akoya Biosciences Inc, (Nasdaq: AKYA) The Spatial Biology Company®, as a premier microscope provider to jointly develop new spatial biology and spatial phenotyping applications.
Avacta announces AffiDX® SARS-CoV-2 antigen lateral flow test detects Delta variant
Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that a study has shown that the AffiDX antigen lateral flow test detects the Delta variant of the SARS-CoV-2 virus in clinical samples and, in this small study, outperformed two lateral flow antigen tests that are…
Orbit Discovery appoints Dr Neil Butt as Chief Executive Officer
Oxford, UK, June 29, 2021: Orbit Discovery Ltd, a biopharmaceutical company focused on discovering candidate peptide therapeutics using high throughput microfluidic platforms, has announced the appointment of Dr Neil Butt as Chief Executive Officer.
Optibrium publishes major peer-reviewed study on AI applications to global pharma data
Published in AI Letters, study collaborators Optibrium, Takeda and Intellegens demonstrated the application of deep learning imputation to a global pharma dataset, offering new insights into drug discovery data that transform how complex data can be used to identify opportunities for new drugs and streamline the drug discovery process.
LegoChem Biosciences and Iksuda Therapeutics expand licence agreement for development of antibody-drug conjugates
Newcastle, UK, 22 June, 2021: Iksuda Therapeutics, the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, today announced that it has expanded its research collaboration and Licence Agreement with LegoChem Biosciences, Inc. (“LCB”) to explore additional ADC programmes which leverage LCB’s proprietary ADC platform technology.
Avacta announces AffiDX® SARS-CoV-2 antigen lateral flow test distribution agreement
Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that it has entered into a non-exclusive distribution agreement with Calibre Scientific Inc, a global provider of life science products, for Avacta’s AffiDX SARS-CoV-2 antigen lateral flow test for professional use in the UK…
The Native Antigen Company wins ‘The Best COVID-19 Responder’ at OBN 2020 Awards
Oxford, UK: The Native Antigen Company, part of LGC Clinical Diagnostics and one of the world’s leading suppliers of reagents that enables research into diagnostics and vaccines for emerging and endemic infectious diseases, won ‘The Best COVID-19 Responder’ at OBN 2020 Awards. The award recognises the Company’s outstanding contribution to the fight against COVID-19.
Enterprise Therapeutics doses first subjects in Phase I trial for novel cystic fibrosis therapy ETD001
Brighton, UK, 14 June 2021: Enterprise Therapeutics Ltd, a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering from respiratory disease, today announced it has successfully dosed the first subjects in a Phase 1 trial for its novel inhaled cystic fibrosis (CF) therapy, ETD001. The first-in-man safety study is being…
Avacta announces registration of its AffiDX SARS-CoV-2 antigen lateral flow test in EU
Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that it has received notice of registration of its AffiDX® SARS-CoV-2 antigen lateral flow test in the EU allowing the Company to place the product on the market in all 27 countries of the EU for professional use.
Bio-Rad introduces three StarBright dyes for flow cytometry
The StarBright Violet 570, StarBright Violet 670, and StarBright Violet 710 dyes offer precise excitation and emission spectra for improved brightness and resolution.
ERS Genomics and genOway enter CRISPR/Cas9 agreement
Dublin, Ireland and Lyon, France, 07 June 2021: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr Emmanuelle Charpentier, and genOway, a leader in conceiving and developing genetically engineered preclinical research models, today announced a non-exclusive licence agreement granting genOway past and future access to…
MHRA confirms registration of Avacta’s AffiDX SARS-CoV-2 antigen lateral flow test
Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the MHRA has confirmed registration of Avacta’s AffiDX® SARS-CoV-2 antigen lateral flow test, allowing the Company to place the product on the market in the UK for professional use.
Iksuda Therapeutics closes $47 million financing round
Newcastle, UK, 07 June 2021: Iksuda Therapeutics, the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, today announced it has completed a US $47 million (circa GB £34 million) financing round, co-led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners, with the Company being advised by Ashfords LLP. The funding will support…
Japanese Patent Office upholds key Charpentier/Doudna CRISPR patent and allows third
Dublin, Ireland, 01 June 2021: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr Emmanuelle Charpentier, today announced that the Japanese Patent Office (JPO) has rejected arguments filed in opposition to the second Japanese patent (JP6692856) filed by Dr.Charpentier, together with The Regents of the University of…
GammaDelta Therapeutics receives FDA Clearance of IND Application for GDX012, a novel allogeneic variable delta 1 gamma-delta T cell cancer therapy
GammaDelta Therapeutics, a company focused on exploiting the unique properties of gamma delta (γδ) T cells for immunotherapy, today announced the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the Company’s allogeneic variable delta 1 (Vδ1) gamma-delta (γδ) T cell therapy, GDX012, to be investigated as a treatment for haematological…
Optibrium and BioPharmics enter partnership on computational drug design
Industry-leading 3D ligand-based design approaches from BioPharmics will be available in StarDrop, Optibrium’s small molecule design and optimisation software.
Charles Fracchia selected for DARPA ISAT Study Group
Boston, US, 18th May 2021: Dotmatics, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced that the US Defense Advanced Research Projects Agency (DARPA) has named Charles Fracchia, Founder of Dotmatics BioBright, to its Information Science and Technology (ISAT) Study…
ERS Genomics and GenScript Biotech Corporation sign CRISPR/Cas9 licence agreement
Dublin, Ireland and Piscataway, New Jersey, 12 May 2021: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr Emmanuelle Charpentier, and GenScript Biotech Corporation (GenScript), the world’s leading research reagent provider, today announced a non-exclusive licence agreement granting GenScript access to ERS Genomics’…
FUJIFILM Irvine Scientific celebrates 50 years of excellence in cell culture
FUJIFILM Irvine Scientific, Inc. is celebrating its 50th year of providing innovative cell culture media products and services. Since its formation, the Company has established a reputation as an innovator and leader in providing cell culture solutions for the Life Science and Medical markets.
Hubrecht Institute licenses Flow Eighteen38 reagent antibodies for cancer research
Porto, Portugal and Utrecht, Netherlands... Flow Eighteen38 and FairJourney Biologics S.A. (FJB), leaders in the discovery and optimization of antibodies, have today announced an agreement with the Hubrecht Institute to harness the potential of FJB’s proprietary llama naïve libraries to develop antibodies to be used as research tools for the group of Hans Clevers.
Bio-Rad launches its Reliance SARS-CoV-2 RT-PCR Assay Kit in Europe
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of the Reliance SARS-CoV-2 RT-PCR Kit (IVD) for European markets after having met the CE-IVD mark requirements.
H.E.L Group appoints Sales Director for Asia-Pacific
H.E.L Group , a global developer and manufacturer of innovative laboratory tools for process optimization, safety, and scale-up, today announced the appointment of Oh Chee Keat (Brice Oh) as Regional Sales Director for Asia-Pacific.
Turbine strengthens R&D capabilities with key appointments
London, UK, Budapest, Hungary... Turbine, a company developing a cell behavior simulation platform to uncover targets for the most challenging cancers, today announced that it has appointed Dr. Mark Velleca as Chair of the Board of Directors. The company also announced that Professor Gordon Mills and Dr Klaus Hoeflich have joined its Scientific Advisory Board (SAB). Drawing on their combined…
H.E.L Group signs distribution agreement with ThalesNano Energy for H-Genie bench-top high-pressure hydrogen generator
London, UK, 27th April 2021: H.E.L Group, a global developer and manufacturer of innovative laboratory tools for process optimisation, safety and scale-up, today announced that it has signed a worldwide non-exclusive distribution agreement with ThalesNano Energy™, a developer of bench-top chemistry-focused gas generators. Covering the H-Genie® bench-top hydrogen generator and associated…
Avacta receives clinical validation of AffiDX SARS-CoV-2 antigen lateral flow test
Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce positive data from the clinical validation of its AffiDX® SARS-CoV-2 antigen lateral flow test. Data from the clinical study conducted in Europe on 98 positive COVID-19 samples demonstrate excellent performance in…